Aluminium in Brain Tissue in Multiple Sclerosis
Mold M, Chmielecka A, Rodriguez MRR, Thom F, Linhart C., King A, Exley C.
Mold M, Chmielecka A, Rodriguez MRR, Thom F, Linhart C., King A, Exley C.
"If the contents of either of the papers became widely known it would surely have sounded the global death knell for the products and also called twelve years of government policy into question. When balancing the welfare of British children against the interests of industry and state it seems in the end the children barely weighed."
Serious ethical questions arise over the role of British Medical Journal and the promotion of Human Papillomavirus vaccines. Back in May BMJ published a news report of the Cochrane Review of HPV vaccines by former London Times journalist Nigel Hawkes “HPV vaccines are effective and safe and work best in young women, review finds”. It has come to light in the blog of Prof David Healy (author Pharmageddon and Let Them Eat Prozac ) that the BMJ knew the reasons for this confidence were at best extremely controversial, and that the journal itself had turned down an earlier paper by members of Nordic Cochrane (including leading scientists Peter Gøtzsche and Tom Jefferson) highlighting major flaws in the science surrounding the products. Healy states:
“ Some months back, the Nordic Cochrane Center, one of the centres in the Cochrane Collaboration, sent a review of studies done on the HPV vaccine to the BMJ. Much to their surprise, BMJ turned down this article which contained all studies done on HPV and a serious attempt to flag up the limitations of the trials and accordingly the limitations of what we could confidently say.”
This paper is still unpublished but two weeks ago BMJ Evidenced Based Medicine published a second paper by the Nordic Cochrane group, Lars Jørgensen, Peter Gøtzsche and Tom Jefferson attacking the foundations of the Cochrane Review, as reported on Age of Autism last week and now available in full from Prof Healy’s site. Despite the BMJ Group publication the main journal chose not to publicise this extraordinarily newsworthy event. (It might be said that news is not what it was and this is one of the most blatant suppressions of the news in modern medicine - the "Fake" comes in not reporting.)
While there is no doubt that the BMJ Group is commercially conflicted, not only accepting advertising from all the manufacturers – GSK, Merck and Sanofi - but also being in historic partnership with Merck, perhaps the real reasons are even more disturbing and relate BMJ’s peculiar relationship as the journal of the British Medical Association (the doctors’ trade union) with the British medical profession. If the contents of either of the papers became widely known it would surely have sounded the global death knell for the products and also called twelve years of government policy into question. When balancing the welfare of British children against the interests of industry and state it seems in the end the children barely weighed.
Last week the present writer tried to challenge a senior BMA member - Dr Peter English, Chair of its Public Health Medicines Committee - in the on-line columns of BMJ:
“As a “Public Health Physician” Peter English seems to express a breath-taking disdain for the public, while also apparently eliding any critical view of vaccines at all with being “anti-science”… I wonder what he thinks the public, particularly prospective vaccinees and their families, should be allowed to know about the recent paper by Jørgensen regarding the inadequacies in the trialing of HPV vaccines?”.
Naturally, it was not published.
PostScript: In a 2008 letter to BMJ regarding HPV vaccine, co-signed by Prof Keith Neal, Peter English discloses:
"Competing interests: Between them the authors have given occasional lectures for, received expenses for professional conferences from, and participated in advisory boards for various pharmaceutical companies, including GlaxoSmithKline, Sanofi Pasteur MSD, and others."
John Stone is UK and European editor of Age of Autism
ABSTRACT: Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and the brains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD.
….An unhealthy microbiome in the mother can make her unborn offspring susceptible to neurodevelopmental disorders. The researchers found that the IL-17a molecule was a key contributor to the development of autism-like symptoms in lab mice.
The good news is that the microbiome can be easily changed, either through diet, probiotic supplements or fecal transplant. All of these approaches seek to restore a healthy equilibrium among the different microorganisms that live in the gut.
“In terms of translating our work to humans, I think the next big step would be to identify features of the microbiome in pregnant mothers that correlate with autism risk,” Lukens said. “I think the really important thing is to figure out what kind of things can be used to modulate the microbiome in the mother as effectively and safely as we can.”
Blocking IL-17a also might offer a way to prevent autism, but it carries much more risk.
“If you think about pregnancy, the body is basically accepting foreign tissue, which is a baby,” said Lukens. “As a result, maintenance of embryonic health demands a complex balance of immune regulation, so people tend to shy away from manipulating the immune system during pregnancy.”.....
But, isn’t vaccinating, manipulating the immune system? We will discuss that more.
Now some may say, when will researchers finally stop blaming mothers for autism? Since the days of Refrigerator Mothers, mothers have had blame thrust upon them when it comes to a diagnosis of autism. Now, it is important to look at the ways a child’s microbiome may become dysfunctional and spiral into autism but is this idea of mom’s gut a true contributor? Some may say it’s a way to distract from the “environmental” sources of immune dysfunction we seem to be catapulted into these days. Let’s take a look.
David Aaronovitch, recent chair of Index on Censorship, Orwell prize winner and Murdoch poodle (or possibly running dog) writing in the London Times wants to stop people saying things he does not like - so perhaps he will not like this article.
The problem with vaccines, is the more you are not allowed to talk about them the more dangerous they will certainly get. You can be fed lots of reassuring information by the surrogates of the people who manufacture them (the health agencies and mainstream journalists) but until ordinary citizens are listened to you will simply be engaged in an ugly strategy of social repression. It is not good enough to tell people when they have been hurt - or worse when their beloved children have been - that the agencies who did the hurting deny it. But for Aaronovitch the products are not mere fallible industrial products, they are simply beyond public criticism.
If anybody is expressing unreasonable faith it is he. If he thinks they are safe, what body of science is he citing, and where are the independent agencies? In the UK the licensing agencies are funded by the industry (the MHRA 100%, the EMA 89%), the chair of the vaccine recommendation committee (the JCVI) is director Oxford Vaccine Group which is commercially involved in developing many of the vaccines the committee recommends. These are all perfectly acceptable arrangements to a mainstream media in advanced decline, and no doubt to our lion of free speech.
In his latest article ‘Conspiracy theorists make monkeys of us all’ (The Times 5 July 2018) Aaronovitch employs all the old bad songs: people who doubt vaccine safety are unscientific and equivalent to those who doubt the theory of evolution; people who doubt vaccine safety are unpleasant right-wing types; people who opposed vaccine mandates in Italy (which incidentally we do not have in the United Kingdom) have caused measles to rise – when he might have focussed on government-pharmaceutical sleaze as the prime cause of their mistrust: the meeting at which Obama put Italian Health Minister Beatrice Lorenzin in charge of global vaccine strategy, the secret deals she signed with GlaxoSmithKline. They probably also knew that she had made up fairy stories about 270 measles deaths among children in London. This was what last year the tens of thousands of people who filled the streets in Italy knew about, unreported by the Italian and global mainstream media, unreported almost certainly in the London Times – just to make them look like idiots. In these circumstances conspiracy was scarcely a theory. Oh yes, and to cap it all they are all “conspiracy theorists”.
We’ve looked at media reports on SCARLET FEVER in the UK, the use of the nasal influenza vaccine in those locations, and research that shows there are biological mechanisms that could connect the two. What may need to happen is laboratory research to look specifically at these connections in an honest and scientific manner.
In the United States, there are some considerations to this situation:
Firstly, the CDC does not track SCARLET FEVER:
Image found here and our thanks.
Secondly, the use of FluMist was stopped for two years but is set to resume in Fall, 2018.
ACIP votes down use of LAIV for 2016-2017 flu season, June 22, 2016
CDC panel again advises against FluMist (2017-2018), Wed June 21, 2017
ACIP: LAIV OK to Use During 2018-19 Flu Season, February 26, 2018 03:59 pm
Thirdly, FluMist will NOT be the first and only choice but an option, and it was NEVER administered in schools as it is in the UK.
AAP: Give children IIV flu shot; use LAIV as last resort, May 21, 2018 : The Academy recommends pediatricians give children inactivated influenza vaccine in the upcoming season and use live attenuated vaccine only as a last resort….Quadrivalent live attenuated influenza vaccine (LAIV4, FluMist), which is given by intranasal spray to healthy patients ages 2 through 49 years, was a popular option for those reluctant to get a shot. While it performed relatively well against influenza B strains, there was modest effectiveness against A/H3N2 strains and no overall effectiveness against A/H1N1 strains. LAIV4 has not been recommended by the AAP and CDC for the past two influenza seasons.
In Part I , we took a look at news articles and data on the increase of scarlet fever in the UK, whilst adding in articles that showed that the LAIV (Live Attenuated Influenza Vaccine) aka the nasal flu shot, has been steadily increased in the UK, in the same time period.
Is it possible that the nasal flu vaccine could somehow result in scarlet fever? Let’s take a look at research for any connections.
Probably the first fact that needs to be illustrated is - Influenza infections increase host susceptibility to bacterial infections in a variety of ways
With influenza, the one we hear about often is pneumonia. In 1918, that seems to have been the pattern, that bacteria, not flu, killed millions . Back to scarlet fever. When penicillin was discovered, the cases and death numbers fell and kept falling. Scarlet fever develops from the organism, S pyogenes, which is classified as a Group A beta-hemolytic streptococcal (GABHS) infection. "Thus, as in the cases of S. pneumoniae and S. aureus, S. pyogenes acts synergistically with influenza viruses and possibly other respiratory viruses in causing secondary bacterial infections. Enhanced adherence and internalization of S. pyogenes to host cells in the presence of influenza virus infection may explain the synergism. 94,95,96
Any form of S. pyogenes infection may potentially lead to systemic manifestations due to release of toxins or superantigens. Scarlet fever typically follows an episode of upper respiratory tract infection,"
Vintage illustration online here and our thanks.
For years now, parents of children on the autism spectrum have been on the internet and social media sharing their stories. Many, like me, have had horror stories of their child being sick too often and then abrupt and bizarre behaviors would appear. Strep throat was often a trigger for us. ---- The strep infection triggers a misdirected immune response causing inflammation within the basal ganglia, a portion of the brain responsible for speech, involuntary movement (tics) and emotion. This inflammation causes an abrupt onset of neurologic and psychiatric symptoms including OCD, tics, anxiety, emotional lability, urinary frequency and sleep disturbances.
While strep is the initial trigger, PANDAS patients can have recurrent symptom exacerbations (flares) later in the disease when exposed to other (non-strep) infections.
We are not crazy. What we have been living is real and our children are very ill.
Fresh research from my favorite group studying PANS and PANDAS in autism, has their study completed - and an abstract published - Anti-neuronal and anti-microbial immunity link CaMKII and autism spectrum disorder with pediatric acute-onset neuropsychiatric syndrome . The full study will be out in late Fall as I had emailed Dr. Cunningham. She is an awesome researcher and a very compassionate person. She shared that she is involved in similar research, Human anti-dopamine receptor 1 monoclonal autoantibody (mAb) identifies potential mechanisms of neuronal signaling in post-infectious autoimmune-mediated neuropsychiatric disease, and as a result, the full papers are coming out later. Let’s take a look at the highlights of the asd abstract:
♦ Autism spectrum disorders (ASD) may be associated with neuropsychiatric symptoms such as tics, obsessive-compulsive behaviors, and other symptoms characteristic of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS).
♦ Functional anti-neuronal autoantibodies which signal CaMKII and induce excess dopamine release were found in ASD/PANDAS serum.
♦ Interestingly, a CamKII mutation has recently been associated with autistic symptoms in animal models and also in ASD in humans. https://www.ncbi.nlm.nih.gov/pubmed/28130356
♦ Children with ASD/PANDAS had significantly elevated anti-neuronal autoantibodies by ELISA, and strong IgG responses against the group A streptococcal epitope GlcNAc were observed in ASD/PANDAS.
Here is an addendum to this post from the study author, Gayle Delong, PhD:
In connection with my paper, the question has been raised: Given that married women who had the HPV shot were less likely to conceive than those who did not receive the shot, were the former more likely to use birth control than the latter? My result that married women who received the shot were less likely to conceive could be explained if those women were more actively trying to prevent pregnancy than married women who did not receive the shot.
The three questions on NHANES that provide insights into contraception are 1) SXQ251: In the past 12 months, how often had you had sex without a condom? 2) RHD442: Are you taking birth control pills now? 3) RHQ520: Are you now using Depo-Provera or injectables to prevent pregnancy?
I seek to determine whether married women who received the HPV shot are more actively seeking to prevent pregnancy than married women who did not receive the shot. I define “actively seeking to prevent pregnancy” as women who at the time of the interview were using condoms at least half the time or taking the birth control pill or receiving an injectable. I find 51.5% of married women who did not receive the shot and 36.6% of married women who received the shot were actively seeking to prevent pregnancy. The 14.9% difference is statistically significant at the 1% level.
This finding suggests that a greater percentage of married women who received the shot should be conceiving compared with married women who did not receive the shot. However, my original study finds that married women who received the shot are less likely to conceive than married women who did not receive the shot. The finding of my original study is not the result of married women who received the HPV vaccine actively avoiding pregnancy more than women who did not receive the HPV shot. I’m happy to discuss details of my results with researchers who are interested.
A lowered probability of pregnancy in females in the USA aged 25–29 who received a human papilloma vaccine injection
Journal of Toxicology and Environmental Health, Part A, DOI: 10.1080/15287394.2018.1477640
ABSTRACT Birth rates in the United States have recently fallen. Birth rates per 1000 females aged 25–29 fell from 118 in 2007 to 105 in 2015. One factor may involve the vaccination against the human papillomavirus (HPV). Shortly after the vaccine was licensed, several reports of recipients experiencing primary ovarian failure emerged. This study analyzed information gathered in National Health and Nutrition Examination Survey, which represented 8 million 25-to-29-year-old women residing in the United States between 2007 and 2014. Approximately 60% of women who did not receive the HPV vaccine had been pregnant at least once, whereas only 35% of women who were exposed to the vaccine had conceived. For married women, 75% who did not receive the shot were found to conceive, while only 50% who received the vaccine had ever been pregnant. Using logistic regression to analyze the data, the probability of having been pregnant was estimated for females who received an HPV vaccine compared with females who did not receive the shot. Results suggest that females who received the HPV shot were less likely to have ever been pregnant than women in the same age group who did not receive the shot. If 100% of females in this study had received the HPV vaccine, data suggest the number of women having ever conceived would have fallen by 2 million. Further study into the influence of HPV vaccine on fertility is thus warranted.
Gayle DeLong, PhD, is an Associate Professor of Economics and Finance in the Bert W. Wasserman Department of Economics and Finance at Baruch’s Zicklin School of Business. Dr. DeLong has published in leading journals, including Journal of Finance, Journal of Financial Economics, Journal of International Money and Finance, Financial Management, and Journal of Financial Research. Research interests include bank acquisitions, regulatory capture, and conflicts of interest. DeLong, the 2013 recipient of the Abraham J. Briloff Prize in Ethics as well as the 2010 recipient of the Zicklin School of Business Teaching Excellence Award, holds a PhD in finance and international business from New York University.
Citation: Gayle DeLong (2018): A lowered probability of pregnancy in females in the USA aged 25–29 who received a human papillomavirus vaccine injection, Journal of Toxicology and Environmental Health, Part A, DOI: 10.1080/15287394.2018.1477640
Since the number of children being diagnosed with autism continues to increase, the research and studies continue to grow as well. Many overlap or years later, they are taken to the next level as our understanding of the science increases. This is such a study.
From the adapted version on Medpage - Baby Teeth May Predict Autism - Zinc and copper metabolism biomarker may lead to new diagnostic tools
Zinc and copper metabolism cycles in the layers of baby teeth may be able to predict which children will develop autism spectrum disorder, a longitudinal analysis suggests.
This is the first study to generate a 90% accurate fetal and early childhood biomarker of autism by tracking metabolic pathways over time and could lead to new diagnostic tools...the researchers found that children who later developed autism had disrupted zinc-copper rhythmicity in utero or in their earliest months of life...We looked at the naturally shed teeth of children and explored them much as you would explore the growth rings of a tree, using them as a sort of retrospective biomarker to see what children were exposed to in the womb and in early life...Prenatal and newborn children form a new tooth layer daily, which captures an imprint of chemicals circulating in the body and produces a chronological exposure record. Zinc and copper pathways are central regulators of multiple metals; disruption of the pathways may have downstream effects that may affect the metabolism of other essential elements and toxic metals.
TOXIC METALS. We don’t see those words enough but there are dozens and dozens of studies showing that environmental toxins are connected to the spectrum of autism.
Here is some very good research on the issues of copper/zinc in the human body .
Important theme from the above new, autism study. Mercury has become a dirty word in autism research. Also that study seems pretty much targeted as a diagnostic tool. There are thousands of children and young adults who would benefit from research dealing with helping them feel and function better. Let’s hope there will be more about that. But here we can see that the issue of copper and zinc is not new in autism. The idea of “disrupted zinc-copper rhythmicity” is new and helpful but let’s look backwards as well:
The frequency of zinc deficiency, copper toxicity and low zinc/copper in children with autism spectrum disorders (ASDs) may indicate decrement in metallothionein system functioning....The plasma zinc/serum copper ratio may be a biomarker of heavy metal, particularly mercury, toxicity in children with ASDs.
Study: Increased Rates of Cervical Cancer in Sweden Linked to Increase in HPV Vaccinations
By Brian Shilhavy
Editor, Health Impact News
A new study published in the Indian Journal of Medical Ethics examined cervical cancer rates among women in Sweden and discovered a link between increased cervical cancer rates among women aged 20-49 during a two-year period between 2014 and 2015, corresponding to increased HPV vaccination rates in this population group, years earlier, when mass HPV vaccinations started in Sweden.
Women above the age of 50, during this two-year period, saw no significant cervical cancer increase and were likely too old to have been vaccinated with the HPV vaccine.
Since the study casts doubt on the efficacy of the HPV vaccine, and, in fact, links the vaccine to increased cancer rates, it is highly unlikely you will read about this in the U.S. corporate-sponsored media, where nothing negative about the blockbuster HPV Gardasil vaccine is allowed.
The study was conducted by Lars Andersson, PhD, from the Department of Physiology and Pharmacology at the Karolinska Institute in Solna, Sweden.
Dr. Andersson states that:
…when the Swedish media discussed the increase in the incidence of cervical cancer, the health authorities were unable to explain the increase.
So Dr. Andersson discussed the possibility that mass HPV vaccination rates actually could be the cause of increased rates of cervical cancer:
HPV vaccination could play a role in the increase in the incidence of cervical cancer. About 25% of cervical cancers have a rapid onset of about three years including progression from normal cells to cancer.
Therefore, an increase may be seen within a short period of time.
Gardasil was approved in Sweden in 2006. In 2010, the vaccination of a substantial number of girls started. In 2010, about 80% of the 12-year-old girls were vaccinated.
Combined with 59% of the 13–18-year-old girls vaccinated through the catch-up programme in the same period, one can say that most girls were vaccinated.
Thus, the oldest girls in the programme were 23 years old in 2015; and this is well within the younger age group shown in Fig. 1.
Dr. Andersson points out that even the FDA’s own analysis of Gardasil in 2006 showed a higher risk of “premalignant cell changes” from the vaccine in certain groups that had already been exposed to some HPV strains:
Read more here.
Controversy has arisen around the Indian Journal of Medical Ethics article because the author had submitted under a false name to escape professional persecution. After consideration the the journal's editors decided not to retract the article and made the following statement:-
On May 8, the KI informed us that its department of physiology and pharmacology did not have any person of this name and requested us to remove the name of the institution. So, on the same day a correction was carried out and the name of KI was removed and duly intimated to KI.
Since then, we have investigated and learned the identity of the author. The author has said that he used a pseudonym because he believed the use of his real name would have invited personal repercussions from those opposed to any questioning of vaccines.
This deception of the journal’s editors is unacceptable. The author could have asked the editors for confidentiality, giving the reasons. Editors may choose to publish articles without revealing the true name of the author, if it is determined that the circumstances justify it.
However, we considered the matter and decided to keep the article on the site as the issues raised by it are important and discussion on it is in the public interest. The author’s true name is withheld at his request.
This study is based on data from middle aged and elderly people echoes the finding of Mawson et al in their pilot study of health outcomes in children (vaccinated vs. unvaccinated) which found "The vaccinated were less likely than the unvaccinated to have been diagnosed with chickenpox and pertussis, but more likely to have been diagnosed with pneumonia, otitis media, allergies and NDD".
Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
© The Author(s). 2018
Received: 18 December 2017
Accepted: 16 April 2018
Published: 27 April 2018
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults.
Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions.
Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7–88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0–678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8–2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75–1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48–1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either.
Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.
Note: Well, at least it's not blaming Mom.
A scientific team led by University of California San Diego School of Medicine researchers says it has identified the cause that may explain why some people develop autism—rare inherited variants in regions of paternal noncoding DNA. Previous studies have demonstrated that de novo mutations contribute to approximately one-third of cases of the disorder.
The current findings (“Paternally Inherited Cis-Regulatory Structural Variants Are Associated with Autism”) are published online in Science.
The newly discovered risk factors differ from known genetic causes of autism in two important ways. First, these variants do not alter the genes directly but instead disrupt the neighboring cis-regulatory elements, or CREs. Second, these variants do not occur as new mutations in children with autism, but instead are inherited from their parents.
"For ten years we've known that the genetic causes of autism consist partly of de novo mutations in the protein sequences of genes" said Jonathan Sebat, Ph.D., a professor of psychiatry, cellular and molecular medicine, and pediatrics at UC San Diego School of Medicine and chief of the Beyster Center for Genomics of Psychiatric Genomics. "However, gene sequences represent only 2% of the genome." Read more here.
I would laugh at the irony if it was not so damn sad and wrong. Paul Offit, a vaccine-maker, profiteer, and head of infectious disease at CHOP, the hub of vaccine industry central, is now asking how is it that children, who have a diagnosis of autism -- and their siblings, are not fully vaccinated? For years now, the research is showing that autism spectrum disorder is an IMMUNE disorder , with the GUT affecting the brain , the bacteria of the gut abnormal , the bacteria types pathogenic , and also that the bacteria is tied to social impairment . Vaccination has been implicated in changing the microbiome, so to blame parents as the reason for their child's increased risk of infections, well, that seems pretty ignorant. The children are at risk of infections as they have a microbiome and immune system that have become dysfunctional, many after their first round of vaccines. Parents did vaccinate but their child's health and well being took a drastic turn. Here is the information that Offit shared with The Inquirer :
"In March, a journal of the American Medical Association published a study defining a new group of children at risk for serious and potentially fatal infections.....Who was this new group? The answer: children with autism spectrum disorder (ASD) and their younger siblings.... Investigators studied 3,729 children with ASD and compared them with 592,907 children without ASD. For vaccines recommended between 4 and 6 years of age (specifically, diphtheria, tetanus, pertussis, polio, influenza, measles, mumps, rubella, and varicella), children with ASD were significantly less likely to be vaccinated than children without ASD. Their younger siblings were also less likely to be vaccinated. Why were parents of children with ASD making this choice? In 1998, British researcher Andrew Wakefield published a study...................."
MMR isn’t the only issue. Some parents have also worried that an ethylmercury-containing preservative called thimerosal, which was commonly used in several vaccines given to young children in the United States...Still, the fears persist. Why? Maybe it’s because the cause or causes of autism haven’t been found and because a cure doesn’t exist."
The study examined children with an asd diagnosis "between ages 4 and 6 years," and that would reflect the time that a second MMR is scheduled, and parents have reported seeing their children regress often after their first MMR vaccine or a combination with that vaccine. Thimerosal, a mercury product, may be another player in microbiome dysfunction because - "Increased mercury levels were detected in stools after vaccination, suggesting that the gastrointestinal tract is involved in ethylmercury elimination , - and this - "As TM (Thimerosal) exposure during the postnatal phase coincided with lactation, some of the TM was delivered through the milk to the GIT [gastrointestinal tract] and may have had an effect on the developing gut microbiome known to be sensitive to heavy metal exposure. "
Remember a lifetime ago when we figured out that not only did the US Childhood vaccine schedule dramatically exceeded the Federal government's recommended daily limit for mercury, but that the limit that they had set was likely many times what it should have been in the first place? For those of you who are new to the issue, a review of the matter from my chapter in Vaccine Epidemic:
"In July of 1999, the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS) issued a joint statement through the Department of Health and Human Services (HHS) on mercury and vaccines. They stated that in the U.S. vaccine program at the time, “some children could be exposed to a cumulative level of mercury over the first six months of life that exceeds one of the federal guidelines.”
The truth was that the amount of mercury in the childhood vaccine schedule grossly exceeded the Environmental Protection Agency’s (EPA) maximum daily adult exposure for methylmercury, the form of mercury most closely related to thimerosal for which the government had established a guideline. The EPA sets the daily limit at 0.1 microgram per kilogram of weight. Based on that guideline, a baby weighing approximately five kilograms (eleven pounds) at two months of age should not receive more than 0.5 micrograms of mercury on the day of a doctor’s visit. At the time the AAP and USPHS joint statement was issued, infants at their two-month visit routinely received 62.5 micrograms of mercury, or 125 times the EPA’s limit. Studies have suggested that, for thimerosal (ethylmercury), “the accepted reference dose should be lowered to between 0.025 and 0.06 micrograms per kilogram per day,” meaning that the exposure at the two-month visit could be as high as 500—rather than 125—times the safe level."
In fact in 1995, Gilbert and Grant-Webster had recommended that the limit be at least cut in half.
Neurobehavioral Effects of Developmental Methylmercury Exposure
Environmental Health Perspectives 103 Suppl 6(Suppl 6):135-42 · October 1995 with 60 Reads
Steven G Gilbert
34.22University of Washington Seattle
Kimberly S. Grant-Webster
Methylmercury (MeHg) is a global environmental problem and is listed by the International Program of Chemical Safety as one of the six most dangerous chemicals in the world's environment. Human exposure to MeHg primarily occurs through the consumption of contaminated food such as fish, although catastrophic exposures due to industrial pollution have occurred. The fetus is particularly sensitive to MeHg exposure and adverse effects on infant development have been associated with levels of exposure that result in few, if any, signs of maternal clinical illness or toxicity. High levels of prenatal exposure in humans result in neurobehavioral effects such as cerebral palsy and severe mental retardation. Prenatal exposure to MeHg in communities with chronic low-level exposure is related to decreased birthweight and early sensorimotor dysfunction such as delayed onset of walking. Neurobehavioral alterations have also been documented in studies with nonhuman primates and rodents. Available information on the developmental neurotoxic effects of MeHg, particularly the neurobehavioral effects, indicates that the fetus and infant are more sensitive to adverse effects of MeHg. It is therefore recommended that pregnant women and women of childbearing age be strongly advised to limit their exposure to potential sources of MeHg. Based on results from human and animal studies on the developmental neurotoxic effects of methylmercury, the accepted reference dose should be lowered to 0.025 to 0.06 MeHg microgram/kg/day. Continued research on the neurotoxic effects associated with low level developmental exposure is needed.
HHS never undertook any review, or made any adjustments.
Well everything old is new again. Drs. Lyons-Weiler and Ricketson have reviewed the dosing of aluminum in the US vaccine program, to find that not only is there a lot of it, and not only does it exceed daily limits, but yet again, the daily limits are not based on sound safety data.
Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum
Journal of Trace Elements in Medicine and Biology Toxicology
Volume 48, July 2018, Pages 67-73
Authors James Lyons-Weiler, Robert Ricketson
• Aluminum levels in vaccine is based on immune efficacy and ignore body weight for safety.
• Several critical mistakes have been made in the consideration of pediatric dosing of aluminum in vaccines.
• Safety inferences of vaccine doses of aluminum have relied solely on dietary exposure studies of adult mice and rats.
• On Day 1 of life, infants receive 17 times more aluminum than would be allowed if doses were adjusted per body weight.
Background: Whole-cell diphtheria–tetanus–pertussis (DTP) and oral polio vaccine (OPV) were introduced to children in Guinea-Bissau in 1981. We previously reported that DTP in the target age group from 3 to 5 months of age was associated with higher overall mortality. DTP and OPV were also given to older children and in this study we tested the effect on mortality in children aged 6–35 months.
Methods: In the 1980s, the suburb Bandim in the capital of Guinea-Bissau was followed with demographic surveillance and tri-monthly weighing sessions for children under 3 years of age. From June 1981, routine vaccinations were offered at the weighing sessions. We calculated mortality hazard ratio (HR) for DTP-vaccinated and DTP-unvaccinated children aged 6–35 months using Cox proportional hazard models. Including this study, the introduction of DTP vaccine and child mortality has been studied in three studies; we made a meta-estimate of these studies.
Results: At the first weighing session after the introduction of vaccines, 6–35-month-old children who received DTP vaccination had better weight-for-age z-scores (WAZ) than children who did not receive DTP; one unit increase in WAZ was associated with an odds ratio of 1.32 (95% CI = 1.13–1.55) for receiving DTP vaccination. Though lower mortality compared with not being DTP-vaccinated was, therefore, expected, DTP vaccination was associated with a non-significant trend in the opposite direction, the HR being 2.22 (0.82–6.04) adjusted for WAZ. In a sensitivity analysis, including all children weighed at least once before the vaccination program started, DTP (±OPV) as the most recent vaccination compared with live vaccines or no vaccine was associated with a HR of 1.89 (1.00–3.55). In the three studies of the introduction of DTP in rural and urban Guinea-Bissau, DTP-vaccinated children had an HR of 2.14 (1.42–3.23) compared to DTP-unvaccinated children; this effect was separately significant for girls [HR = 2.60 (1.57–4.32)], but not for boys [HR = 1.71 (0.99–2.93)] (test for interaction p = 0.27).
Conclusion: Although having better nutritional status and being protected against three infections, 6–35 months old DTP-vaccinated children tended to have higher mortality than DTP-unvaccinated children. All studies of the introduction of DTP have found increased overall mortality.
Polio is an enterovirus, and it's not the only enterovirus capable of causing paralysis. Enteroviruses are fairly common, most people who become infected have no or few symptoms. If symptoms develop, they are like a cold or mild flu. One enterovirus that has been in the news lately is called "EV-D68" which can cause polio-like paralysis they call "acute flaccid myelitis (AFM)". CDC acknowledges this.
What turns an asymptomatic or low-symptom harmless enterovirus infection into an ER visit and hospitalization? In 1995, researchers figured out that with the polio enterovirus, it was intramuscular injections within 30 days of being given a live polio vaccine. They were studying cases of "provocation" poliomyelitis following receipt of live polio vaccine.
Like other enteroviruses, 95% of polio infections are asymptomatic or very mild. Polio only very rarely leads to paralysis. Researchers in 1998 stated: "Muscle injury due to injection of vaccines or therapeutic agents is common in medical practice. It has been observed that, if concurrent with PV infection, such injury may increase the risk of neurological complications."
PV is polio virus, but as noted above, other commonly circulated enteroviruses can lead to paralysis.
With children today being given so many intramuscular injections so often throughout childhood, odds are a seemingly well child will actually be infected with (and successfully fighting) an enterovirus when given a round of vaccines.
And with the ACIP dangerously telling pediatricians it's OK to vaccinate mildly ill children, those who have earaches or are on antibiotics, the odds increase that a child infected with an enterovirus will be given a round of vaccines, possibly leading to AFM.
How can this be prevented?
How many times have we been told that "correlation does not equal causation" regarding autism and vaccine injury? Except when it does. American children have been lab rats for more than two decades as medical interventions have taken over infancy and toddlerhood. How many babies can not hold down food and are on antacid meds? WHY ARE BABIES ON ANTACIDS? All roads lead to the GUT and microbiome. Funny, wasn't "that doctor" from England a gastroenterologist? Imagine what his research could have done for children had he not been pilloried by Pharma and governments....
Once vaccines are finally "correlated" pharma is going to have a big ache in their tum Tums......
Antacids, antibiotics for infants linked to later allergies
Infants who are given antacids like Zantac or Pepcid are more likely to develop childhood allergies, perhaps because these drugs may alter their gut bacteria, a new large study suggests.
Early use of antibiotics also raised the chances of allergies in the study of nearly 800,000 children.
Researchers combed the health records of kids born between 2001 and 2013 and covered by Tricare, an insurance program for active duty and retired military personnel and their families. A surprising 9 percent of the babies received antacids, reflecting the popularity of treating reflux in infancy.
Over four years, more than half of all the children developed allergies to foods or medications, rashes, asthma, hay fever or other allergic diseases. The study couldn’t prove causes, but the connection with antacids and antibiotics was striking.For children who received an antacid during their first six months, the chances of developing a food allergy doubled; the chances of developing a severe allergic reaction called anaphylaxis or hay fever were about 50 percent higher. For babies who received antibiotics, the chances doubled for asthma and were at least 50 percent higher for hay fever and anaphylaxis.
Note: Food has always been the starting point of health since "an apple a day," and all that. Many of us have found some relief from the symptoms of autism via dietary changes. Some have had life altering successes for their kids. Still others, nothing. I read the local Mom lists on Facebook and am shocked at how many women suffer from migraines. And then ask where is the best take out XYZ food in the next breath. Below is a study may help you talk to your child's doctor about dietary interventions, or perhaps quell your Mother-In-Law's stink eye at the Passover table.
Comprehensive Nutritional and Dietary Intervention for Autism Spectrum Disorder—A Randomized, Controlled 12-Month Trial
The beginning of it goes into a strange array of gene talk but then the focus of the article is this---
Some signals associated with a cell type called microglia were far higher in the samples from people with autism than from samples of people with other conditions. This signal may be higher because the microglia are more active. If that’s true, an antibiotic that reduces their activity could be one way to treat the condition—which is what UCLA Health psychiatrist and one of the authors of the study, Dr. Michael Gandal, is testing right now....
He and his colleagues are working to recruit about 30 adults for a brain-imaging study to look at their microglia and take an antibiotic called minocycline for 12 weeks.
“Throughout the 12 weeks, we measure a set of cognitive tasks, and we repeat the brain imaging," he said. "The idea is to look at how levels of inflammation in the brain relate to cognitive and behavioral function in individuals with autism.”
Autism spectrum disorders (ASD) are highly disabling, persistent neurodevelopmental disorders. There are no available treatments for core symptoms of ASD or biologically-based clinical biomarkers. Emerging evidence indicates that levels of brain inflammation are increased in ASD. In particular, recent work implicates hyperactivity of microglial cells, the resident immune cells of the brain. However, the functional consequences of microglial activation remain unknown. This study will measure microglial activation in ASD using positron emission tomography (PET) brain imaging. Adult males with ASD (n=15) and healthy controls (n=15) will be recruited for this study and undergo comprehensive clinical and behavioral baseline assessment. All subjects will then undergo baseline PET imaging using a radiotracer that labels activated microglia. Subjects with ASD will then undergo 12-week open label treatment with minocycline, an FDA-approved antibiotic thought to block microglial activation. PET imaging will be repeated at 12 weeks to confirm target engagement. A subset of control subjects will also undergo repeat PET imaging to determine test-retest reliability. During minocycline treatment, ASD subjects will be evaluated every 2 weeks for safety, clinical impression, behavioral functioning, and measures of cognition. Results will provide important information regarding the relationship between levels of brain inflammation, cognitive and behavioral function in ASD.
I am hoping that more candidates can join as it looks like almost a year since it's been updated. Let's take a look at Minocycline and see if we can't get more people excited and involved in this type of research.
It's been about six years since I really started putting a focus on autism and bacterial infections. Because I have a daughter who has a diagnosis of autism and also an autoimmune diagnosis, the immune system has become a key player in my research to help her. The MICROBIOME research has exploded and its connection to the MICROGLIA of the brain may be a big part in autism spectrum disorders.
There are far too many children and young adults who suffer. The list of painful and debilitating symptoms grows as parents watch in agony. Patterns tend to emerge:
CHRONIC VIRAL and BACTERIAL INFECTIONS
Metabolic Brain Disease, July 2017
The conceptualisation of autistic spectrum disorder and Alzheimer’s disease has undergone something of a paradigm shift in recent years and rather than being viewed as single illnesses with a unitary pathogenesis and pathophysiology they are increasingly considered to be heterogeneous syndromes with a complex multifactorial aetiopathogenesis, involving a highly complex and diverse combination of genetic, epigenetic and environmental factors. One such environmental factor implicated as a potential cause in both syndromes is aluminium, as an element or as part of a salt, received, for example, in oral form or as an adjuvant. Such administration has the potential to induce pathology via several routes such as provoking dysfunction and/or activation of glial cells which play an indispensable role in the regulation of central nervous system homeostasis and neurodevelopment. Other routes include the generation of oxidative stress, depletion of reduced glutathione, direct and indirect reductions in mitochondrial performance and integrity, and increasing the production of proinflammatory cytokines in both the brain and peripherally. The mechanisms whereby environmental aluminium could contribute to the development of the highly specific pattern of neuropathology seen in Alzheimer’s disease are described. Also detailed are several mechanisms whereby significant quantities of aluminium introduced via immunisation could produce chronic neuropathology in genetically susceptible children. Accordingly, it is recommended that the use of aluminium salts in immunisations should be discontinued and that adults should take steps to minimise their exposure to environmental aluminium.
Evidence of the neurotoxicity of aluminium cations (Al3+) includes: an association between chronic aluminium exposure and the development of AD; the involvement of aluminium adjuvants in the development of ASIA; and epidemiological evidence pointing to an association between the use of aluminium adjuvants and ASD. There is good evidence to suggest that immunisation may accelerate or precipitate the transition between subclinical and overt symptomatic autoimmune conditions within the first 30 days post-immunisation, particularly in those younger than 50 years of age. The immune response to immunisation may be influenced by variations in HLA, TLR and cytokine genes. Moreover, aluminium exposure is associated with the production of pro-inflammatory cytokines and chemokines and with the development of chronic oxidative stress, mitochondrial dysfunction and glial activation or dysfunction; these changes in turn are associated with ASD.
Note: LabCorp has received a patent on a method for diagnosing autism spectrum disorders.
Abstract: The invention generally relates to methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.
The method, invented by David Michael Margulies and Mark Firman Bear of Massachusetts, involves taking a tissue or body sample from a subject and then conducting a test to identify variant sequences in the subject’s genetic code, which may signify “the presence or an increased risk of developing autism spectrum disorders.” Testing can be done on children and fetuses, according to the patent.
The method is stated to aid in the diagnosis of five autism spectrum disorders, all of which fall under the umbrella of pervasive developmental disorders: autistic disorder, Asperger’s disorder, childhood disintegrative disorder, Rett’s disorder, and nonspecific pervasive developmental disorders.
The method claims to have multiple applications, each of which provides insight into the biological basis of autism spectrum disorders through different lenses.
By Teresa Conrick
2017 had good and bad attached to it. For many of us, the death of our dear colleague and friend, Dan Olmsted, has saddened many a day since..... Dan did much innovative research and writing for years to expose the issues that bring us all here daily. Age of Autism has become a refuge for years now, to so many looking for truth and answers. As we enter 2018, I would like to keep with that tradition by sharing my list of what I think is important and innovative in the science area of autism. It's imperative that families know that there is good research happening but unfortunately, there's a hell of a lot of bad research about autism, and often we hear about that too much.... especially the mulri-million dollars wasted on genes (have you seen the constant SPARK, pop-up infomercials on Facebook, a nowhere odyssey of genetic, musical chairs?) We need real research to help so many who suffer with the many symptoms of autism - painful GI disease; seizures; inability to speak or communicate in a meaningful manner or, at all; extreme sensory disturbance; executive functioning disability; debilitating obsessions, compulsions and tics; acute anxiety; heartbreaking self-injurious behaviors; and the daily struggles with social cues. Much of this originates in the gut.
Studies on Causation
NOTE: You might recall that a "freezer malfunction" at Harvard University destroyed one third of the world's largest autistic brain collection. Can you imagine the information lost?
J.B. Handley has written about this paper at his Medium site - STAFFORDSHIRE, England — Professor Chris Exley is a formidable scientist, which is perhaps more important than you think, because a study he published today with his colleagues in the Journal of Trace Elements in Medicine and Biology may just be the “smoking gun” to prove that vaccines are triggering autism that we’ve all been waiting for. Professor Exley is a Professor of Bioinorganic Chemistry at Keele University in Staffordshire, England. He received a Ph.D. in a subject that makes him highly qualified to author this latest paper: “the ecotoxicology of aluminium.”
Autism spectrum disorder is a neurodevelopmental disorder of unknown aetiology. It is suggested to involve both genetic susceptibility and environmental factors including in the latter environmental toxins. Human exposure to the environmental toxin aluminium has been linked, if tentatively, to autism spectrum disorder. Herein we have used transversely heated graphite furnace atomic absorption spectrometry to measure, for the first time, the aluminium content of brain tissue from donors with a diagnosis of autism. We have also used an aluminium-selective fluor to identify aluminium in brain tissue using fluorescence microscopy. The aluminium content of brain tissue in autism was consistently high. The mean (standard deviation) aluminium content across all 5 individuals for each lobe were 3.82(5.42), 2.30(2.00), 2.79(4.05) and 3.82(5.17) μg/g dry wt. for the occipital, frontal, temporal and parietal lobes respectively. These are some of the highest values for aluminium in human brain tissue yet recorded and one has to question why, for example, the aluminium content of the occipital lobe of a 15 year old boy would be 8.74 (11.59) μg/g dry wt.? Aluminium-selective fluorescence microscopy was used to identify aluminium in brain tissue in 10 donors. While aluminium was imaged associated with neurones it appeared to be present intracellularly in microglia-like cells and other inflammatory non-neuronal cells in the meninges, vasculature, grey and white matter. The pre-eminence of intracellular aluminium associated with non-neuronal cells was a standout observation in autism brain tissue and may offer clues as to both the origin of the brain aluminium as well as a putative role in autism spectrum disorder.
Read the full study http://www.sciencedirect.com/science/article/pii/S0946672X17308763http://www.sciencedirect.com/science/article/pii/S0946672X17308763
or view the pdf below.
We have made the first measurements of aluminium in brain tissue in ASD and we have shown that the brain aluminium content is extraordinarily high. We have identified aluminium in brain tissue as both extracellular and intracellular with the latter involving both neurones and non-neuronal cells. The presence of aluminium in inflammatory cells in the meninges, vasculature, grey and white matter is a standout observation and could implicate aluminium in the aetiology of ASD
NOTE: James Lyons-Weiler PhD asked Facebook readers to share this piece from his blog, because Facebook was feeling cranky toward the topic. Please bookmark James Lyons-Weiler.com.
Please read the original post for copious graphic backup and the full entry.
WHEN DR. CHRIS EXLEY and his research team discovered aluminum co-localized with amyloid plaques in the brains of patients who died from Alzheimer’s, it made big news, even though a study in 1985 discussed the aluminum silicate portion of amyloid. That’s right. We’ve known since 1985 at least that amyloid plaque in the brain is partly aluminum silicate. Now, Exley’s findings completely destroy any hope that aluminum somehow stayed out of the brain,
Aluminum, it turns out, plays a critical role in our understanding of the biological mechanisms of vaccine injury. In this article, I will review the scientific evidence of four major ways that vaccines can cause harm. These are (1) Vaccine-Induced Mitopathy; (2) Vaccine-Induced Persistent Gliosis; (3) Vaccine-Induced Endoplasmic Reticulum Damage, and (4) Vaccine-Induced Autoimmunity (to appear as a separate article). My intent and purpose is not and has never been to discourage anyone from accepting vaccines, nor to provide medical advice of any kind; rather, my intent is to make a clear path toward safer routes to artificial immunization and communicate the state of scientific knowledge about mechanisms of the pathophysiology of disease caused by vaccines, and how such human pain and suffering can be mitigated.
mitopathy(1) Vaccine-Induced Mitopathy
Individuals born with mitochondrial disorders have partially disable cellular energetics. Mutations that alter proteins in the various specific mitochondrial pathways lead to a variety of congenital conditions, including encephalomyopathy and seizures. We need mitochondria to work in all of our tissues. However, our brains consume so much energy, any weakening of mitochondrial ATP flux will almost certainly lead to neurological disorders.
Environmental damage to mitochondria is known to occur from exposure to lead and includes depletion of mitochondrial membrane potential (ΔΨ) and intracellular glutathione (GSH), elevation of caspase-3 activity, intracellular reactive oxygen species, and malondialdehyde levels, and inhibition of GSH peroxidase (GSH-Px) activity (Liu et al., 2014).
Why discuss lead-induced mitochondrial toxicity in an article on vaccine injury? In part because many individuals familiar with brain injuries and conditions that lead to brain injuries will recognize the critical role of GSH, the importance of shutting down ROS, and the potential use of malondialdehyde as a screen for brain injury following vaccination. Another reason is that 25% of the homes in Pittsburgh have higher lead levels in the water coming into the homes than the levels found in the water in Flint, MI, and individuals with mitochondrial damage due to lead are likely to be a higher risk of the toxic effects from vaccines.
The science of the specific actions and mechanisms of mitochondrial injury from vaccines include some of these events, including recognition of aluminum as an intracellular ROS generator (Han et al., 2013). Aluminum is present in vaccines as an adjuvant in a variety of forms, most commonly aluminum hydroxide (a well-known neurotoxin). Vaccine risk denialists spend a lot of time denying the massive literature on the neurotoxicity of aluminum. Nevertheless, studies show that aluminum also disrupts cytoskeletal dynamics (Lemire et al., 2009).
Thimerosal also has damaging influences on mitochondria, including direct damage to the mitochondrial genome. Sharpe et al. (2012) found that thimerosal induced a five-fold increase in the levels of oxidant damaged mitochondrial DNA bases and increases in the levels of mtDNA nicks and blunt-ended breaks. Read more here.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Sep;2(6):518-527. doi: 10.1016/j.bpsc.2017.06.008.
Linke AC1, Olson L1,2, Gao Y1,2, Fishman I1, Müller RA1.
Prescription of psychotropic medications is common in autism spectrum disorders (ASDs), either off-label or to treat comorbid conditions such as ADHD or depression. Psychotropic medications are intended to alter brain function. Yet, studies investigating the functional brain organization in ASDs rarely take medication usage into account. This could explain some of the inconsistent findings of atypical brain network connectivity reported in the autism literature.
The current study tested whether functional connectivity patterns, as assessed with functional magnetic resonance imaging (fMRI), differed in a cohort of 49 children and adolescents with ASDs based on psychotropic medication status, and in comparison with 50 matched typically developing (TD) participants. Twenty-five participants in the ASD group (51%) reported current psychotropic medication usage, including stimulants, antidepressants, antipsychotics, and anxiolytics. Age, IQ, head motion, and ASD symptom severity did not differ between groups. Whole-brain functional connectivity between 132 regions of interest was assessed.
Different functional connectivity patterns were identified in the ASD group taking psychotropic medications (ASD-on), as compared to the TD group and the ASD subgroup not using psychotropic medications (ASD-none). The ASD-on group showed distinct underconnectivity between the cerebellum and basal ganglia but cortico-cortical overconnectivity compared to the TD group. Cortical underconnectivity relative to the TD pattern, on the other hand, was pronounced in the ASD-none group.
These results suggest that psychotropic medications may affect functional connectivity, and that medication status should be taken into consideration when studying brain function in autism.
We were asked to see if any parents out there might like to join a study on the MICROBIOME and AUTISM :
Researchers at Stanford University School of Medicine and the South San Francisco pharmaceutical company Second Genome Inc. have jointly received a $2.1 million grant to recruit subjects for a study exploring potential links between bacteria in the gut — known as the microbiome — and autism, the company announced Tuesday.
Researchers have long suspected, based on anecdotal evidence, that there may be a link between the microbiome and the severity of an autism diagnosis. There is limited data demonstrating the link in humans, but some studies indicate it may exist in lab mice.
Many children with autism have food allergies or gut conditions such as inflammatory bowel diseases, leading researchers to hypothesize that activity in the gut has a relationship to autism, said Dennis Wall, an associate professor of pediatrics at Stanford who is co-leading the study. With the new grant from the National Institutes of Health, the researchers will attempt to test that theory, so doctors can better diagnose and design therapies for people on the autism spectrum.
Here are the details - (uploading a video is optional)
We are looking for 100 families with two or more children, where:
The study procedures include responding to an online behavioral and dietary survey, uploading a 3-minute home video, and collecting stool and saliva samples at home for each child. Everything is completed either online or in the home.
Would you be willing to send out this study information to your email listserv and/or post on your social media platforms (Facebook, Twitter, etc)? We only need 40 more families to participate and we are so excited to start analyzing the data!
Please see our most recent press release on SF Chronicle here, a KQED press release, our recruitment flyer attached, and our study website to sign up now! If you have any questions, please don’t hesitate to ask.
The M3 Team
I just want to add that Stanford is also making progress on PANDAS and PANS, in fact they do research on that as well and actually have a team of experts and immune therapies . But when you look at the AUTISM clinic there , it is dismal and archaic and has very little to do with the immune system, although we know that for many autism patients with moderate to severe symptoms, the immune system is key, as we see in this study, Pediatric autoimmune neuropsychiatric syndrome (PANS), developmental regression and autism.
“This book is a masterpiece and a must-read for anyone with concerns about the safety and efficacy of vaccines.”
—Stephanie Seneff, PhD, senior research scientist, MIT
Leave a comment and enter to win a copy. New from Skyhorse Publishing. Buy now!
Richard Moskowitz, MD, is a family physician who received his BA from Harvard, Phi Beta Kappa, his MD from New York University, and a US Steel Fellowship in Philosophy at the University of Colorado. He has been in private practice since 1967. After studying herbs, Japanese acupuncture, and other holistic modalities, he has specialized in homeopathic medicine since 1974, and has written four previous books and over a hundred articles on homeopathy, midwifery, natural healing, and the philosophy of medicine. He resides in Boston, Massachusetts.
An experienced family doctor reexamines the risks and benefits of vaccines and our public health policy.
Dr. Richard Moskowitz, a Harvard-educated family doctor with more than forty-five years of clinical experience treating children, examines vaccines and our current policy regarding them. His book Vaccines (Skyhorse Publishing hardcover; September 19, 2017; $27.99) offers an ensemble of observed facts, clinical and basic science research, news reports from the media, and actual cases from his practice, Dr. Moskowitz provides an overview of the subject in a respectful and thoughtfully reasoned manner.
He shows how vaccines, by their very nature, have a major downside that has largely been ignored and is built into their design, and explores how it is reckless to continue mandating them until their dangers are taken seriously, understood in a broader context, and assessed in a more careful and systematic fashion.
He also presents evidence that the risks of vaccination are compounded by the concerted efforts of pharmaceutical companies, the CDC, and the doctors who speak for them to keep them hidden. Writing with a sense of urgency, Dr. Moskowitz advocates for making vaccines optional, while the country seems to be moving in the opposite direction. He believes that parents should be able to exercise their moral and legal right to choose which treatments are appropriate for their children, and which diseases, if any, to vaccinate their children against. Above all, he hopes to promote a healthy debate and to encourage more of the rigorous scientific work that still needs to be done.
Axios has obtained an internal message from the CDC's public affairs officer, Jeffrey Lancashire, dated August 31, to all CDC employees. His directive to them was to stop talking to the media, “even for a simple data-related question.”
The memo reads:
"Effective immediately and until further notice, any and all correspondence with any member of the news media, regardless of the nature of the inquiry, must be cleared through CDC's Atlanta Communications Office. This correspondence includes everything from formal interview requests to the most basic of data requests."
Axios tried to contact Mr. Lancashire to find out more about the policy; however, he has not responded.
Why is even basic data being treated like state secrets?
It's almost like the CDC has something to hide.
THIS JUST IN:
CDC HAS RELEASED A VIDEO EXPLAINING TO THE PUBLIC WHY THEIR NEW STANCE IS NECESSARY:
Not even Kaiser Permanente have been able to completely fudge the association between the vaccine and autism in this study, after exchanges with Brian Hooker and Donzelli et al. Here is the abstract:-
JAMA Pediatr. 2017 Jan 2;171(1):e163609. doi: 10.1001/jamapediatrics.2016.3609. Epub 2017 Jan 2.
Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder.
Maternal infections and fever during pregnancy are associated with increased risk for autism spectrum disorders (ASDs). To our knowledge, no study has investigated the association between influenza vaccination during pregnancy and ASD.
To investigate the association between influenza infection and vaccination during pregnancy and ASD risk.
Design, Setting, and Participants:
This cohort study included 196 929 children born at Kaiser Permanente Northern California from January 1, 2000 to December 31, 2010, at a gestational age of at least 24 weeks.
Data on maternal influenza infection and vaccination from conception date to delivery date, obtained from Kaiser Permanente Northern California inpatient and outpatient databases. Influenza infection was defined by the International Classification of Diseases, Ninth Revision, Clinical Modification codes or positive influenza laboratory test results.
NOTE: Seems like since Mrs. Wright's death last year, Autism Speaks has changed its mission from "It's time to listen," to "It's time to give up." What a sin. Let's live with autism. Cancer. Alzheimers. Diabetes. MD. Raise money and live with it. Disgusting in the extreme.
By Ginger Taylor, MS
Just saw a new Autism Speaks commercial. The message...
"Learn to live with it."
I kid you not.
(Let's just skip past the horrid imagery of a child with autism on a boat in the water with no supervision for the sake of time and trauma.)
For the few people who don't see a problem with this or understand why so many of us are so angry, please contrast compare two possible positions here. The first has been espoused by our community for more than a decade, the second is espoused by Autism Speaks.
1. Autism is preventable and medically treatable.
2. Autism, learn to live with it.
The first is accurate and appropriate, as there are medical treatments for people diagnosed with autism that will alleviate the symptoms of autism (some of which are life threatening... re: children in a boat in the water with no supervision). This will make their lives better without them having to spend hours and weeks and years combating a terribly debilitating condition. If there is medical treatment available for a debilitating condition, is ethical to tell people that there is medical treatment available for their debilitating condition.
Autism Research Institute is presenting a Webinar tomorrow, 4/12 titled: Immunological Issues in ASD - Gestational Influences. Register here. From ARI:
Join Judy Van de Water, PhD to learn about gestational influences on neurodevelopment.
Dr. Van de Water joined the faculty in the Department of Internal Medicine at the University of California, Davis in 1999. In 2000, she also joined the faculty of the newly formed UC Davis M.I.N.D. Institute when she began her research on the immunobiology of autism. Dr. Van de Water’s laboratory pursues research programs pertaining to autoimmune and clinical immune-based disorders including the biological aspects of autism spectrum disorders. The application of Dr. Van de Water’s immunopathology background has been instrumental in the dissection of the immune anomalies noted in some individuals with autism, and in the differentiation of various autism behavioral phenotypes at a biological level. Most notable of these is the investigation of the maternal immune system as it relates to autism spectrum disorders, with particular emphasis on the presence of highly specific maternal autoantibodies to fetal brain proteins.
NOTE: We're pleased to share this interview from our sponsor Safeminds. While many of our own children can not self-advocate, and the term has become tarnished by many in the Neurodiversity movement, it's important and we welcome those with autism who can help our kids to do so. Thanks, Lisa Wiederlight of Safeminds and James. Please visit the Safeminds site here.
An Interview with James Williams, Autistic Advocate, SafeMinds Communications Committee Member
Last year, SafeMinds Executive Director Lisa Wiederlight, had the privilege of interviewing James Williams, a 27 year-old man with autism. James is a bright, highly-intelligent advocate for and representative of the autism community. The text of the interview follows.
Please tell us about yourself, and provide some information on your background.
I am an adult with autism, age 27, who has lived with autism all of my life. Though my official diagnosis of autism was at the age of three, in 1991, I was filmed extensively as an infant as part of a research project to showcase "normal" child development, and this footage has revealed that my autism emerged at birth.
My diagnosis at the age of three was the product of two things--an "explosion" of autism symptoms that increased at 18-months that included a digression of language, and my parent's belief that my digression was a product of the "terrible two's," a belief that had to be discarded when I turned three and the behavior did not change.
I underwent many therapies and interventions growing up--physical therapy, occupational therapy, theraplay, auditory integration training, and speech therapy--you name it, I had it, with two notable exceptions--ABA therapy and psychotropic drugs. My parents did not believe in ABA or drugs, and refused to give me such interventions.
After a highly-successful early intervention where I regained full language, I began my presenting career at the age of 11, answering questions after a presentation by parent advocate Annabel Stehli that was organized by auditory therapist Terrie Silverman. This led to a full-time career as a traveling presenter that I continue today. I am also the author of three books, Out to Get Jack, The H.A.L. Experiment, When Gary Comes to Play. I have served on the leadership team for Camp R.O.C.K.S., a summer camp for individuals with autism, from 2007 to 2012, and also a professional musician who plays the recorder.
NOTE: Can you think of a product more fraught with injury? From the poisoning scandal decades ago, to heavy metal pieces found in the product, to the actual usage causing a cascade of chemical changes linked to autism. One day, Tylenol will be viewed like Thalidomide. Soon, we hope.
Jennifer Margulis, co-author of The Vaccine Friendly Plan with Dr. Paul Thomas posted this on Facebook:
Breaking news: A team of researchers from Duke University School of Medicine and Harvard University have just this morning published a comprehensive review article in the peer-reviewed JOURNAL OF INTERNATIONAL MEDICINE showing scientifically how acetaminophen is a MAJOR FACTOR in DAMAGING CHILDREN'S BRAINS.
"The use of acetaminophen in babies and young children may be much more strongly associated with autism than its use during pregnancy, perhaps because of well-known deficiencies in the metabolic breakdown of pharmaceuticals during early development. Thus, one explanation for the increased prevalence of autism is that increased exposure to acetaminophen, exacerbated by inflammation and oxidative stress, is neurotoxic in babies and small children. This view mandates extreme urgency in probing the long-term effects of acetaminophen use in babies and the possibility that many cases of infantile autism may actually be induced by acetaminophen exposure shortly after birth," the 9 scientists write.
Please take the time to READ this study and SHARE it with your doctor, nurse practitioner, hospital worker, or other healthcare provider. And please tag any JOURNALISTS you know and encourage them to write about it: http://journals.sagepub.com/doi/pdf/10.1177/0300060517693423
The wide range of factors associated with the induction of autism is invariably linked with either inflammation or oxidative stress, and sometimes both. The use of acetaminophen in babies and young children may be much more strongly associated with autism than its use during pregnancy, perhaps because of well-known deficiencies in the metabolic breakdown of pharmaceuticals during early development. Thus, one explanation for the increased prevalence of autism is that increased exposure to acetaminophen, exacerbated by inflammation and oxidative stress, is neurotoxic in babies and small children. This view mandates extreme urgency in probing the long-term effects of acetaminophen use in babies and the possibility that many cases of infantile autism may actually be induced by acetaminophen exposure shortly after birth
Gastroenterol Clin North Am. 2017 Mar;46(1):77-89. doi: 10.1016/j.gtc.2016.09.007. Epub 2017 Jan 4.
The Microbiome-Gut-Brain Axis in Health and Disease.
Gut microbes are capable of producing most neurotransmitters found in the human brain. Evidence is accumulating to support the view that gut microbes influence central neurochemistry and behavior. Irritable bowel syndrome is regarded as the prototypic disorder of the brain-gut-microbiota axis that can be responsive to probiotic therapy. Translational studies indicate that certain bacteria may have an impact on stress responses and cognitive functioning. Manipulating the gut microbiota with psychobiotics, prebiotics, or even antibiotics offers a novel approach to altering brain function and treating gut-brain axis disorders, such as depression and autism.
Study to investigate connection between antibiotic use and autism symptoms
By Kevin Barry
Today, a groundbreaking new study of the overall health of vaccinated and unvaccinated children has been released to the public for the first time. The critically important new pilot study has been posted on line.
The paper was leaked to journalist and author James Grundvig, who published an article describing aspects of the study on Medium on February 22, 2017. Grundvig describes how the paper was leaked to him (and others?), and he describes how he authenticated it with the study’s author and with the journal which censored it.
I will list a few of the many reasons why this paper is critically important at this time.
1. The #RFKcommission.
This study provides numerous clues for potential future research. It may help serve as a blueprint for the RFK Commission in the United States and for other countries.
I’ve read numerous beautiful tributes to brilliant, wonderful and fearless Dan Olmsted on Age of Autism over the past month. I’m not nearly as talented a writer as those who have honored Dan on these pages. I didn’t know how I could help honor him … until now. Dan tried for more than a decade to get a vaccinated vs. unvaccinated study done, and he pioneered the concept with his series on the Amish.
Please help guide us Dan, and thank you for your dedication to all of our children.
First Study of Vaccinated versus Unvaccinated Children - Censored by an International Scientific Journal - Now Public Vaccination and Health Outcomes: A Survey of 6- to 12-year-old Vaccinated and Unvaccinated Children based on Mothers’ Reports, was censored by the journal Frontiers in Public Health.
Key Study Findings
Background: The long-term health outcomes of the routine vaccination program remain unknown. Studies have been recommended by the Institute of Medicine to address this question.
Specific Aims: To compare vaccinated and unvaccinated children on a broad range of health outcomes, and to determine whether an association found between vaccination and neurodevelopmental disorders (NDD), if any, remained significant after adjustment for other measured factors.
Environmental Research Magazine
Vaccines are prophylactics used as the first line of intervention to prevent, control and eradicate infectious diseases. Young children (before the age of six months) are the demographic group most exposed to recommended/mandatory vaccines preserved with Thimerosal and its metabolite ethylmercury (EtHg). Particularly in the less-developed countries, newborns, neonates, and young children are exposed to EtHg because it is still in several of their pediatric vaccines and mothers are often immunized with Thimerosal-containing vaccines (TCVs) during pregnancy. While the immunogenic component of the product has undergone more rigorous testing, Thimerosal, known to have neurotoxic effects even at low doses, has not been scrutinized for the limit of tolerance alone or in combination with adjuvant-Al during immaturity or developmental periods (pregnant women, newborns, infants, and young children). Scientific evidence has shown the potential hazards of Thimerosal in experiments that modeled vaccine-EtHg concentrations. Observational population studies have revealed uncertainties related to neurological effects. However, consistently, they showed a link of EtHg with risk of certain neurodevelopment disorders, such as tic disorder, while clearly revealing the benefits of removing Thimerosal from children's vaccines (associated with immunological reactions) in developed countries. So far, only rich countries have benefited from withdrawing the risk of exposing young children to EtHg. Regarding Thimerosal administered to the very young, we have sufficient studies that characterize a state of uncertainty: the collective evidence strongly suggests that Thimerosal exposure is associated with adverse neurodevelopmental outcomes. It is claimed that the continued use of Thimerosal in the less-developed countries is due to the cost to change to another preservative, such as 2-phenoxyethanol. However, the estimated cost increase per child in the first year of life is lower than estimated lifetime cost of caring for a child with a neurodevelopmental disorder, such tic disorder. The evidence indicates that Thimerosal-free vaccine options should be made available in developing countries.
Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society?
Analyses of data and hidden agenda behind repeated failed outcomes of cancer research and therapy, status of American health, safety concerns for HPV vaccines and future research considerations are summarized in this commentary. A closer look at cancer science reveals that highly power structure (system) in medical establishment vs. anti-system and chaos in cancer research (‘medical/scientific ponzi schemes’) is potent recipe for failed therapeutics that kills patients but generates huge corporate profit. American health status ranks last among other developed nations despite the highest amount that USA invests in healthcare. This is a wake-up call to make sure that the evil part of human being does not prevent the health services that the public deserves. Otherwise, ‘it does not matter how many resources you have, if you don’t know, or don’t want to know, how to use them, they will never be enough’. Answer to cancer and improved public health is possible only by switching the current corruptive and abusive culture of ‘who you know’ to a culture of ‘what you know’. Policy makers and professionals in decision making roles are urged to return to common sense and logics that our Forefathers used to serve the public.
UPDATE; *Purchase a hard copy of The Environmental and Genetic Causes of Autism now through Black Friday, November 25, and email a copy of your receipt, along with your full name and mailing address (U.S. only), to firstname.lastname@example.org.
Visit the Skyhorse site to shop at your favorite bookseller.
We’ll send you a complimentary copy of Sarah Bridges' A Bad Reaction.
Black Friday promotion from
By Lou Conte
Every now and then a book emerges that alters the landscape of scientific, political and societal dialogue. The Environmental and Genetic Causes of Autism is that kind of book, from Skyhorse Publishing.
Like Rachel Carson’s seminal on the impact of pesticides on the environment, Silent Spring, Lyons-Weiler’s work will be controversial, and may well anger some of his colleagues in the scientific hegemony. This book directly confronts well-entrenched viewpoints on causality that clings with fervent faith that there is no autism epidemic, and that autism is a genetic disorder.
Lyons-Weiler confronts these topics with over 1,000 studies that scientists have published but which those in position to sway public health policy have, until now, failed, or simply chosen, to not acknowledge.
The Environmental and Genetic Causes of Autism delves deeply and comprehensively into the full body of past and current research. The work reflects an unbiased perspective on the various molecular mechanisms at work in autism, and it reveals how genetic predispositions and environmental factors can combine and interact to produce the diagnoses of autism and autism spectrum disorders (ASD). An often-denied wealth of studies showing association of autism with vaccines is also reviewed.
Int J Risk Saf Med. 2016 Sep 17;28(3):125-41. doi: 10.3233/JRS-160726.
Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.
To investigate possible linkages between neurodevelopmental delay and neurodevelopmental spectrum disorders and exposure to medication with effects on serotonin reuptake inhibition during pregnancy.
We systematically reviewed the epidemiological literature for studies bearing on this relationship in children born with neurodevelopmental spectrum disorder and related conditions, as well as animal studies giving serotonin reuptake inhibitors to pregnant animals and in addition reviewed the literature for proposals as to possible mechanisms that might link effects on serotonin reuptake with cognitive changes post-partum.The epidemiological studies were analysed to produce Forest plots to illustrate possible relations.
The odds ratio of Autistic Spectrum or related Disorders in children born to women taking serotonin reuptake inhibiting antidepressants during pregnancy in case control studies was 1.95 (95% C.I. 1.63, 2.34) and in prospective cohort studies was 1.96 (95% C.I. 1.33, 2.90).
There appears to be a link between serotonin reuptake inhibition in pregnancy and developmental delay and spectrum disorders in infancy leading to cognitive difficulties in childhood. More work needs to be done to establish more precisely the nature of the difficulties and possible mechanisms through which this link might be mediated.
Autism spectrum disorder; antidepressants; neurodevelopmental delay; neurodevelopmental spectrum disorders; pregnancy; serotonin reuptake inhibitors
Immunol Res. 2016 Jul 14. [Epub ahead of print]
Adjuvants- and vaccines-induced autoimmunity: animal models.
Ruiz JT1,2, Luján L3, Blank M2, Shoenfeld Y4,5.
The emergence of autoimmunity after vaccination has been described in many case reports and series. Everyday there is more evidence that this relationship is more than casual. In humans, adjuvants can induce non-specific constitutional, musculoskeletal or neurological clinical manifestations and in certain cases can lead to the appearance or acceleration of an autoimmune disease in a subject with genetic susceptibility. The fact that vaccines and adjuvants can trigger a pathogenic autoimmune response is corroborated by animal models. The use of animal models has enabled the study of the effects of application of adjuvants in a homogeneous population with certain genetic backgrounds. In some cases, adjuvants may trigger generalized autoimmune response, resulting in multiple auto-antibodies, but sometimes they can reproduce human autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, autoimmune thyroiditis and antiphospholipid syndrome and may provide insights about the potential adverse effects of adjuvants. Likewise, they give information about the clinical, immunological and histologic characteristics of autoimmune diseases in many organs, especially secondary lymphoid tissue. Through the description of the physiopathological characteristics of autoimmune diseases reproduced in animal models, new treatment targets can be described and maybe in the future, we will be able to recognize some high-risk population in whom the avoidance of certain adjuvants can reduce the incidence of autoimmune diseases, which typically results in high morbidity and mortality in young people. Herein, we describe the main animal models that can reproduce human autoimmune diseases with emphasis in how they are similar to human conditions.
About ten months ago I started writing a new book, INOCULATED: How Science Lost Its Soul in Autism, which would utilize the CDC whistleblower story as a way to review the corruption in science regarding vaccines and autism. I knew Andy Wakefield was working on his documentary, and when I interviewed him for this book he mentioned it, but in my wildest dreams I never imagined VAXXED would explode onto the scene the way it has. I have been writing furiously to make sure that story is included as well.
In the meantime, I got a powerhouse agent, Johanna Maaghoul of the Waterside Literary Agency, the world's #1 agency for New York Times non-fiction bestsellers. Johanna has been taking the book around to publishing companies, getting some positive interest, but they are absolutely terrified of the subject. Publishing companies like to sell books, so that's where you come in. I want you to read the chapter outline and if this is a book you would like to buy, leave a comment to that effect. How's that for simple? That way when my agent is talking to a publisher she can say something like, "Five hundred and seventy two people said they would buy this book immediately!" Thanks in advance for your comments.
Chapter One: The Call – Dr. Brian Hooker, a university biology professor was working in his office when he got a call from a senior Centers for Disease Control and Prevention (CDC) scientist, Dr. William Thompson. The two worked together years earlier when parent groups were clamoring for the CDC to conduct research into vaccines and autism. Thompson reveals that the CDC found such evidence, but covered it up. Thompson had retained these documents and eventually turned them over to Congressman William Posey. The most explosive of these allegations is that earlier administration of the MMR vaccine is causing a 3.36-fold increase in autism among African-American males. With Thompson’s guidance, Hooker publishes this information in the summer of 2014.
Chapter Two: The Insanely Good Soul of Dr. Andrew Wakefield – British researcher, Dr. Andrew Wakefield first published his findings suggesting the MMR vaccine was linked to autism in The Lancet in 1997, even going so far as to share these results with the CDC prior to publication. In the ensuing years, Wakefield was subjected to unbelievable persecution and his name was vilified throughout the world. Hooker brings the Thompson documents to Wakefield’s attention. Hooker also initiates contact between Thompson and Wakefield, with Thompson apologizing for participating in the cover-up of research that would have vindicated Wakefield’s research. Wakefield accepts Thompson’s apology.
Journal of American Physicians and Surgeons
Volume 21 Number 2 Summer 2016
Although health authorities including the Centers for Disease Control and Prevention (CDC) claim that childhood vaccines are safe and recommend combining multiple vaccines during one visit, a review of data from the Vaccine Averse Event Reporting Sstem (VAERS) shows a dose-dependent association between the number of vaccines administered simultaneously and the likelihood of hospitalization or death for an adverse reaction. Additionally, younger age at the time of the adverse reaction is associated with a higher risk of hospitalization or death
Read the full article here.
About one in 10 youths treated with an antipsychotic are diagnosed with autism spectrum disorder or intellectual disability. Conversely, one in six youths diagnosed with autism spectrum disorder has been prescribed antipsychotics. Furthermore, the results suggest that the proportion of adolescents with autism or intellectual disability has increased among youths treated with antipsychotics and that more youths with autism or intellectual disability have received antipsychotics.
About one in ten youths treated with an antipsychotic are diagnosed with autism spectrum disorder or intellectual disability. Conversely, one in six youths diagnosed with autism spectrum disorder has been prescribed antipsychotics. These findings are reported in the June 2016 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP). Furthermore, the results suggest that the proportion of adolescents with autism or intellectual disability has increased among youths treated with antipsychotics and that more youths with autism or intellectual disability have received antipsychotics.
Currently, second-generation antipsychotics are the only FDA-approved medications for youth with autism. However, these are approved only for the symptomatic control of irritability and aggression. They do not have an indication for youth with intellectual disability, and they do not seem to affect the core symptoms of autism spectrum disorders, such as social and communication difficulties, or the core symptoms of intellectual disability, such as problems with understanding and responding appropriately to information from the outside world.
Performing a meta-analysis of 39 studies and over 350,000 youth with mental illness, a group of researchers led by Christoph U. Correll, MD, of Hofstra Northwell School of Medicine, examined the frequency and time trends of antipsychotic prescribing in youth with autism spectrum disorders or intellectual disability, mostly drawing on data from large registry-based studies.
"Although the increased prescribing of antipsychotics in youth with autism spectrum disorders or intellectual disability cannot be judged as appropriate or inappropriate based on database studies, side effects of antipsychotics can be quite problematic, especially in children and adolescents," said Correll. "Therefore, clinicians should perform very careful risk: benefit evaluation before and after starting youth with autism spectrum disorders or intellectual disability on an antipsychotic, always trying to maximize non-pharmacologic interventions as well as pharmacologic or non-pharmacologic treatments for comorbidities, including attention-deficit/hyperactivity disorder, anxiety disorders, obsessive-compulsive disorder, and sleep disorders."
Based on the study results and the known adverse effects of antipsychotics, the authors concluded that clinicians should consider using psychosocial interventions that are proven to be efficient for behavioral dysregulation such as irritability and aggression, before prescribing antipsychotics to adolescents with autism or intellectual disability. The authors further stressed that when prescribing antipsychotics, it is imperative to regularly monitor both their efficacy and tolerability in patients through body weight, fasting lipids and glucose, extrapyramidal side effects, sedation, and sexual/reproductive adverse effects, and to manage abnormalities appropriately.
Published on Nov 11, 2014
We’ve been studying the impact of toxins on children for the past 30 years and reached the inescapable conclusion: little things matter. We’ve discovered that extremely low levels of toxins can impact brain development. We have also discovered that subtle shifts in the intellectual abilities of individual children have a big impact on the number of children in a population that are challenged or gifted. Steps should be taken to reduce children's exposure to toxins or suspected toxins. You can read more about how toxins impact brain development and the supportive documentation for this video here: The Impact of Toxins on the Developing Brain Annual Review of Public Health
Pletz J, et al. Toxicology. 2016.
A latency period preceding neurotoxicity is a common characteristic in the dose-response relationship induced by organic mercury. Latency periods have typically been observed with genotoxicants in carcinogenesis, with cancer being manifested a long time after the initiating event. These observations indicate that even a very small dose may cause extensive adverse effects later in life, so the toxicity of the genotoxic compound is dose and time-dependent. In children, methylmercury exposure during pregnancy (in utero) has been associated with delays in reaching developmental milestones (e.g., age at first walking) and decreases in intelligence, increasing in severity with increasing exposure. Ethylmercury exposure from thimerosal in some vaccines has been associated, in some studies, with autism and other neurological disorders in children. In this paper, we have examined whether dose-response data from in vitro and in vivo organic mercury toxicity studies fit the Druckrey-Küpfmüller equation c·t(n)=constant (c=exposure concentration, t=latency period), first established for genotoxic carcinogens, and whether or not irreversible effects are enhanced by time of exposure (n≥ 1), or else toxic effects are dose-dependent while time has only minor influence on the adverse outcome (n<1). The mode of action underlying time-dependent toxicity is irreversible binding to critical receptors causing adverse and cumulative effects. The results indicate that the Druckrey-Küpfmüller equation describes well the dose-response characteristics of organic mercury induced neurotoxic effects. This amounts to a paradigm shift in chemical risk assessment of mercurial compounds and highlights that it is vital to perform toxicity testing geared to investigate time-dependent effects.
Copyright © 2016. Published by Elsevier Ireland Ltd.
26945727 [PubMed - as supplied by publisher]
Nathaniel W. Hodgson,
Malav S. Trivedi,
Hamid M. Abdolmaleky,
Kim Quang Do,
Richard C. Deth
Published: January 22, 2016
Many studies indicate a crucial role for the vitamin B12 and folate-dependent enzyme methionine synthase (MS) in brain development and function, but vitamin B12 status in the brain across the lifespan has not been previously investigated. Vitamin B12 (cobalamin, Cbl) exists in multiple forms, including methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl), serving as cofactors for MS and methylmalonylCoA mutase, respectively. We measured levels of five Cbl species in postmortem human frontal cortex of 43 control subjects, from 19 weeks of fetal development through 80 years of age, and 12 autistic and 9 schizophrenic subjects. Total Cbl was significantly lower in older control subjects (> 60 yrs of age), primarily reflecting a >10-fold age-dependent decline in the level of MeCbl. Levels of inactive cyanocobalamin (CNCbl) were remarkably higher in fetal brain samples. In both autistic and schizophrenic subjects MeCbl and AdoCbl levels were more than 3-fold lower than age-matched controls. In autistic subjects lower MeCbl was associated with decreased MS activity and elevated levels of its substrate homocysteine (HCY). Low levels of the antioxidant glutathione (GSH) have been linked to both autism and schizophrenia, and both total Cbl and MeCbl levels were decreased in glutamate-cysteine ligase modulatory subunit knockout (GCLM-KO) mice, which exhibit low GSH levels. Thus our findings reveal a previously unrecognized decrease in brain vitamin B12 status across the lifespan that may reflect an adaptation to increasing antioxidant demand, while accelerated deficits due to GSH deficiency may contribute to neurodevelopmental and neuropsychiatric disorders.
Read more Decreased Brain Levels of Vitamin B12 in Aging, Autism and Schizophrenia.
By Ginger Taylor
So, yesterday I posted an email I had written to Dr. Tom Insel, head of IACC. You can read it here. I asked if someone could please send me Autism Speaks' Rob Ring's email. And someone kindly obliged. Here's the email I sent to Rob Ring. Both of the emails are a response to the post Katie Wright ran on Thursday regarding the complete and total and seemingly purposeful disregard both Ring and Insel have for meaningful autism research.
|Subject:||Vaccine Autism Research|
|Date:||Fri, 14 Aug 2015 16:36:37 -0400|
This is in the context of broad disapproval and frustration within the autism community over NIH funding priorities. The general level of concern was documented by a 2008 letter signed by eleven major autism organizations (including Autism Speaks, Autism Research Institute, Safeminds, Autism Society of America, Generation Rescue, National Autism Association). The letter stated, "Research on the environment, gene-environment interaction and treatment are underrepresented...." There seems to be great frustration among these groups and others that regardless of acts of Congress, directives or calls for serious investigation into how the environment triggers persons predisposed to autism, there is too much research focused on genetics to the detriment of studies of environmental triggers.
The Inter-Agency Autism Committee (IACC) developed a plan that included serious research spending on investigating autism's environmental causes. Their strategic plan was published. In 2009 there was a program to increase federal spending (the "ARRA" funds related to the need to stimulate the economy out of recession and into recovery) and NIH announced a multitude of new funding opportunities as a result. There was a long "Research Funding Announcement" (RFA) which is a call for scientists to submit proposals to spend available grant money on their research interests.
Persons who get their PhDs in a scientific field learn how to get grants to support their research interests. One thing that is often done is to send an initial, short letter of inquiry, to get some feedback on how to pitch a full application for grant monies. Full applications are big long documents, sometimes 100 pages or more.
Like many researchers employed at a university, I receive emails from my university's grant office calling my attention to new funding opportunities that might be a good match, and I was encouraged to consider the ARRA grant opportunities from NIH. I noted there were a lot of RFA's (the full document was 181 pages!). I searched for calls with the word Autism in the announcement: there were ten. Eight clearly did not match the environmental intent of the strategic plan; they were about developing registries or comparing treatments. One was about gene and environment interactions but mentioned determining specific genetic variations and seemed to require genotyping. Only one mentioned the Interagency Autism Coordinating Committee (IACC) Strategic Plan and measuring biomarkers. This one looked good.
It was the only RFA on the NIH website posted (out of 181 pages of short postings) that mentioned the IACC strategic plan or seemed to be a fit for measures of Autism's environmental triggers or exposures. The NIH document included available grant opportunities for all branches of NIH (including NIEH, NIMH etc). I then looked up the IACC strategic plan and read it carefully. It seemed like a great fit. The RFA I inquired about read:
04-MH-101* Autism: Addressing the challenge. Target research gap areas identified by the Inter-Agency Autism Coordinating Committee (IACC) Strategic Plan for Autism Spectrum Disorder Research, including biomarkers, novel interventions, and new tools for screening, among other topics. Contact: Dr. Ann E. Wagner, 301-443-5944, email@example.com [Note: Ann E Wagner is currently a branch chief at NIMH, the part of NIH directly that houses the IACC]
My plan was to measure toxic levels in the environment, and then directly measure the levels in children with autism and controls (biomarkers of), and correlate levels to symptoms. In this way, I could establish norms for measured biomarkers based on measured environmental exposures among typical children, and then compare those with ASD to the norms. Possibly (this is what I hoped to check), if levels were higher than expected based on similar exposure in autistic children, this would point towards vulnerability to exposure and efforts could be made to limit toxic exposures in vulnerable children. It was a good match to the strategic intent of the IACC plan because I planned to measure biomarkers of exposure, which could lead to a novel intervention. I took the time to look at the IACC strategic plan (since it was directly mentioned in the funding announcement I was interested in pursuing). I located it and read it carefully to see if my aims were congruent. They were. To wit, the IACC website strategic plan on USA's Health and Human Services website (HHS.gov) included these key statements:
Initiate studies on at least five environmental factors identified in the recommendations from the 2007 IOM report.
Identify and standardize at least three measures for identifying markers of environmental exposures.
Determine the effect of at least five environmental factors on risk for subtypes of ASD.
From my read, out of the 181 page NIH document and hundreds of their RFA's, this was quite clearly the only possible match for what I wanted to do, which was to measure environmental exposure both environmentally and via biomarkers, among children with and without autism, and compare to symptom expression which could suggest strategies for intervention. However, I also had a specific methodological question about the possibility of including initial testing of a brand new technology being developed by some physicists to measure toxins. This prompted me to send a short inquiry via email. This is what I wrote.
> -----Original Message-----
> From: Cathy DeSoto [mailto:firstname.lastname@example.org]
> Sent: Thursday, March 19, 2009 5:25 PM
> To: Wagner, Ann (NIH/NIMH) [E]; Rob Hitlan
> Subject: 04-MH-101 Autism: Addressing the challenge
> We are interested in applying for the grant referred to below and will
> be submitting an application in early April. I have read the Interagency
> autism committee strategic plan and believe our aims would be a good match.
> The overall goal will be to investigate environmental risk factors,
> primarily via sources of pollution/toxic emissions from the perspective
> of genetic susceptibility for toxins having neurological effects,
> although we do not intend to measure genotype in anyway. We intend to
> propose direct measures of toxins among those with an ASD and controls
> (blood, hair or both) as well as measures of toxins in the environment
> relating to prevalence patterns, all of which will be elaborated upon in
> the actual proposal, of course.
> My reason for writing is to inquire if it would be appropriate to
> include a relatively small portion of the budget for testing of new
> spectroscopy instrumentation for the purpose of quantifying
> environmental toxins. Because we will already be proposing measures of
> toxins (for example soil samples via a grid layout in pockets of high
> prevalence) and because the new spectroscopy technique would be expected
> to allow easier and more highly accurate measures than is currently
> available (which would be explained in the full proposal), it would be a
> cost effective way to validate the method. Once validates, it is
> possible the new technique would be highly useful in relating toxins to
> health outcomes such as autism.
Conclusions Most vaccine trials are published eventually or the results posted in ClinicalTrials.gov, but delays to publication of several years are common. Actions should focus on the timely dissemination of data from vaccine trials to the public.
BMJ 2014;348:g3058 doi: 10.1136/bmj.g3058 (Published 16 May 2014)
Lamberto Manzoli associate professor 1 2, Maria Elena Flacco resident physician 1 3, Maddalena D’Addario resident physician 4 5, Lorenzo Capasso PhD student 1 Corrado De Vito assistant professor 6, Carolina Marzuillo assistant professor 6, Paolo Villari professor 6, John P A Ioannidis professor 7 8 1Department of Medicine and Aging Sciences, University of Chieti, Via dei Vestini 5 66013 Chieti, Italy; 2CeSI Biotech, Via Colle dell’Ara, Chieti, Italy; 3Local Health Unit of Pescara, Italy; 4Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Switzerland; 5Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Switzerland; 6Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy; 7Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; 8Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
Objective To evaluate the extent of non-publication or delayed publication of registered randomized trials on vaccines, and to investigate potential determinants of delay to publication.